UPJOHN's MINOXIDIL/RETINOIC ACID CLINICAL STUDY FOR BALDNESS
UPJOHN's MINOXIDIL/RETINOIC ACID CLINICAL STUDY FOR BALDNESS is slated to be underway by March in five centers in the U.S. The eight-month study will include 200 patients. The additive effect of retinoic acid with minoxidil will be studied in comparison with minoxidil alone for the treatment of baldness and thinning hair. Retinoic acid is currently used in Rx acne treatments. The Upjohn trials are designed in part to explore results of clinical research published in the October 1986 Journal of the American Academy of Dermatology. Authored by Gail Bazzano, PhD, Nia Terasakis, MD, and Wesley Galen, MD (New Orleans), the studies showed that after one year, the combination of topical tretinoin (trans-retinoic acid) with 0.5% minoxidil resulted in "terminal hair regrowth" in 66% of subjects. Results were based on several small pilot studies conducted between 1983 and 1986. Topical tretinoin was administered alone and in combination with minoxidil to 56 subjects with androgenetic alopecia. Tretinoin alone was shown to stimulate some hair regrowth in approximately 58% of the subjects. According to the study, "tretinoin has been shown to promote and regulate cell proliferation and differentiation in the epithelium and may promote vascular proliferation. These factors are important for hair growth promotion." At a recent presentation to stock analysts in New York, Upjohn Senior VP Mark Novitch noted that an 11-center, 300-patient, 32-week study is underway in the U.S. to assess the effectiveness of minoxidil in women with alopecia or hair thinning. A similar program is beginning in Europe, Novitch added. Because the centers conducting the studies are on different schedules, it may be a couple of years before the research program is completed, an Upjohn spokesperson said. If results are promising, the firm expects to file an NDA for the new indication. Upjohn is also sponsoring U.S. studies on minoxidil for alopecia areata or patchy baldness, Novitch said. The results of studies in more than 500 patients are currently being analyzed. The company may decide to conduct further research based on the analysis.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth